Search ↗

Best of

The safest peptides, defined as the ones with actual human safety data

Safe means studied, not mild. A compound that has been through regulatory review has a characterised side-effect profile. A compound with no human data has an unknown one, however gentle it feels. This list is the former.

By Lindy Health editorial Updated 18 Oct 2026
How we ranked these Regulator-approved compounds only, ranked by breadth of safety data and absence of serious signals. Full criteria in our methodology.

Quick answer

#CompoundClassEvidenceReported rangeStatus
1 Semaglutide GLP-1 & incretins Regulator approved 250 mcg - 2.4 mg Prescription
2 Tesamorelin GHRH analogs Regulator approved 1-2 mg Prescription
3 Sermorelin GHRH analogs Regulator approved 200-500 mcg Prescription
4 Melanotan I Melanocortins Regulator approved 500 mcg - 1 mg Prescription
5 PT-141 Melanocortins Regulator approved 1-2 mg Prescription

The ranking

01

Semaglutide

Regulator approved GLP-1 & incretins

Around ninety human trials and years of post-marketing surveillance. Side effects are common, well characterised, and overwhelmingly gastrointestinal. The thyroid C-cell signal is from rodents and remains a boxed warning.

Evidence~90 human studies
Reported range250 mcg - 2.4 mg
Half-life~7 days
Banned in sportNo
Full Semaglutide record → Find a prescriber
SSemaglutide
02

Tesamorelin

Regulator approved GHRH analogs

Approved with a clean safety record in HIV lipodystrophy trials. Arthralgia and injection-site reactions dominate. Glucose tolerance needs monitoring.

Evidence~15 human studies
Reported range1-2 mg
Half-life~26-38 minutes
Banned in sportYes
Full Tesamorelin record → Find a prescriber
TTesamorelin
03

Sermorelin

Regulator approved GHRH analogs

Decades of clinical use including in children, with a benign profile. Acts upstream of the pituitary so negative feedback remains intact.

Evidence~20 human studies
Reported range200-500 mcg
Half-life~10-20 minutes
Banned in sportYes
Full Sermorelin record → Find a prescriber
SSermorelin
04

Melanotan I

Regulator approved Melanocortins

Approved as an implant for erythropoietic protoporphyria. MC1R-selective, so it avoids the nausea and erectile effects of melanotan II. Naevus darkening still requires monitoring.

Evidence~12 human studies
Reported range500 mcg - 1 mg
Half-life~1 hour (implant gives sustained release)
Banned in sportNo
Full Melanotan I record → Find a prescriber
MMelanotan I
05

PT-141

Regulator approved Melanocortins

Approved for hypoactive sexual desire disorder. Nausea is common; transient blood-pressure rise is the reason for the cardiovascular contraindication.

Evidence~20 human studies
Reported range1-2 mg
Half-life~2.7 hours
Banned in sportNo
Full PT-141 record → Find a prescriber
PPT-141

What we left out, and why

BPC-157
No human safety data exists. It may well be benign. Nobody has checked.
Melanotan II
Non-selective, with safety warnings from multiple national regulators.
Adipotide
Nephrotoxic in primates.

Head-to-head comparisons

Sermorelin vs TesamorelinSemaglutide vs TesamorelinMelanotan I vs PT-141Semaglutide vs TirzepatideLiraglutide vs SemaglutideRetatrutide vs SemaglutideAOD-9604 vs SemaglutideCJC-1295 vs Tesamorelin

References for the compounds in this guide

  1. Wilding JPH, Batterham RL, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.Diabetes Obes Metab 2022.PubMed 35441470 · doi:10.1111/dom.14725
  2. Rubino DM, Greenway FL, Khalid U, et al.. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.JAMA 2022.PubMed 35015037 · doi:10.1001/jama.2021.23619
  3. Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity.N Engl J Med 2021.PubMed 33567185 · doi:10.1056/NEJMoa2032183
  4. Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.JAMA 2021.PubMed 33755728 · doi:10.1001/jama.2021.3224
  5. Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.N Engl J Med 2025.PubMed 40353578 · doi:10.1056/NEJMoa2416394
  6. Wharton S, Freitas P, Hjelmesæth J, et al.. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.Lancet Diabetes Endocrinol 2025.PubMed 40961952 · doi:10.1016/S2213-8587(25)00226-8
  7. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.N Engl J Med 2023.PubMed 37952131 · doi:10.1056/NEJMoa2307563
  8. Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med 2021.PubMed 34170647 · doi:10.1056/NEJMoa2107519
  9. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  10. Mayfield CK, Bolia IK, Feingold CL, et al.. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med 2026.PubMed 41476424 · doi:10.1177/03635465251357593
  11. Badran AS, Helal A, Shata KS, et al.. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.Obes Res Clin Pract 2026.PubMed 41545261 · doi:10.1016/j.orcp.2026.01.002
  12. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  13. Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.Drugs 2011.PubMed 21668043 · doi:10.2165/11202240-000000000-00000
  14. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.Ann Pharmacother 2012.PubMed 22298602 · doi:10.1345/aph.1Q629
  15. Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci 2026.PubMed 42123471 · doi:10.3390/ijms27093890
  16. Corley MJ, Letendre SL, Nightingale S. CROI 2024: Neuropsychiatric Complications in People With HIV.Top Antivir Med 2024.PubMed 39746672
  17. Memdouh S, Gavrilović I, Ng K, et al.. Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug Test Anal 2021.PubMed 34665524 · doi:10.1002/dta.3183
  18. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?.Clin Interv Aging 2006.PubMed 18046908 · doi:10.2147/ciia.2006.1.4.307
  19. Ramirez G, Herrera R, Pineda D, et al.. The effects of high altitude on hypothalamic-pituitary secretory dynamics in men.Clin Endocrinol (Oxf) 1995.PubMed 7641401 · doi:10.1111/j.1365-2265.1995.tb01887.x
  20. Coutinho LFD, DE Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.J Sports Med Phys Fitness 2026.PubMed 41880199 · doi:10.23736/S0022-4707.26.17773-1
  21. Popovic V, Pekic S, Golubicic I, et al.. The impact of cranial irradiation on GH responsiveness to GHRH plus GH-releasing peptide-6.J Clin Endocrinol Metab 2002.PubMed 11994347 · doi:10.1210/jcem.87.5.8485
  22. Saenger P, Pescovitz OH, Bercu BB, et al.. Outcome of growth hormone therapy in children with growth hormone deficiency showing an inadequate response to growth hormone-releasing hormone.Endocrine 2001.PubMed 11572326 · doi:10.1385/ENDO:15:1:051
  23. Perez-Bootello J, Cova-Martin R, Naharro-Rodriguez J, et al.. Vitiligo: Pathogenesis and New and Emerging Treatments.Int J Mol Sci 2023.PubMed 38139134 · doi:10.3390/ijms242417306
  24. Bayerl C. [Undesirable pigmentation].Hautarzt 2015.PubMed 26315100 · doi:10.1007/s00105-015-3671-4

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page ranks published reference data. It is not medical advice and not a recommendation to use any compound. Several compounds documented on this site are not approved for human use.